StreetInsider.com News Articles

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer.

The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Lilly’s Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

Mon, 01 Jun 2026 09:05:00 -0400

These Biotech Stocks Have Critical Phase 2 and/or Phase 3 Milestones Ahead

Form 8-K Olema Pharmaceuticals, For: May 26

Tue, 26 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260526/26545758.html

Form 8-K Olema Pharmaceuticals, For: May 26

Tue, 26 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260526/26545758.html

H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)

Fri, 22 May 2026 06:54:46 -0400

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $38.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).

The analyst commented: "Yesterday after market close, ASCO abstracts were released, and Olema announced a poster presentation on Phase 1 data for OP-3136 (KAT6 inhibitor) in ER+/HER2- advanced breast cancer and a trial in progress poster for the Phase 3 OPERA-02 trial of palazestrant + ribociclib in 1L ER+/HER2- metastatic breast cancer. The Phase 1 OP-3136 data had a cut-off of March 2, 2026, with 32 patients enrolled, and 19 patients response evaluable (this was updated vs the abstract which had data from

Form 8-K Olema Pharmaceuticals, For: May 21

Thu, 21 May 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260521/26536693.html

Form 8-K Olema Pharmaceuticals, For: May 21

Thu, 21 May 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260521/26536693.html

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

Olema Oncology (NASDAQ: OLMA) announced preliminary results from its phase 1 study of OP-3136, an experimental cancer treatment targeting the KAT6 protein. The company presented the data at the American Society of Clinical Oncology Annual Meeting.

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.

According to the company, no dose-limiting toxicities were observed across the tested dose range, and no patients discontinued treatment due to drug-related side effects. The most common treatment-related adverse events included taste changes

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.

Olema Oncology reports early phase 1 data for cancer drug OP-3136

Thu, 21 May 2026 17:00:58 -0400

The study enrolled 32 patients with advanced solid tumors who had received multiple prior treatments. OP-3136 was administered orally once daily at doses ranging from 2 mg to 45 mg in 28-day cycles.